2oz7
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:2oz7.jpg|left|200px]] | [[Image:2oz7.jpg|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_2oz7", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | + | {{STRUCTURE_2oz7| PDB=2oz7 | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate''' | '''Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate''' | ||
| Line 30: | Line 27: | ||
[[Category: Miller, D D.]] | [[Category: Miller, D D.]] | ||
[[Category: Wu, Z.]] | [[Category: Wu, Z.]] | ||
| - | [[Category: | + | [[Category: Androgen receptor]] |
| - | [[Category: | + | [[Category: Anti-androgen]] |
| - | [[Category: | + | [[Category: Prostate cancer]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 11:58:33 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 08:58, 4 May 2008
Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate
Overview
Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer. Compared with steroidal agonists for the androgen receptor (AR) (e.g. dihydrotestosterone, R1881), CPA is bulkier in structure and therefore seemingly incompatible with the binding pockets observed in currently available x-ray crystal structures of the AR ligand-binding domain (LBD). We solved the x-ray crystal structure of the human AR LBD bound to CPA at 1.8A in the T877A variant, a mutation known to increase the agonist activity of CPA and therefore facilitate purification and crystal formation of the receptor.drug complex. The structure demonstrates that bulk from the 17alpha-acetate group of CPA induces movement of the Leu-701 side chain, which results in partial unfolding of the C-terminal end of helix 11 and displacement of the loop between helices 11 and 12 in comparison to all other AR LBD crystal structures published to date. This structural alteration leads to an expansion of the AR binding cavity to include an additional pocket bordered by Leu-701, Leu-704, Ser-778, Met-780, Phe-876, and Leu-880. Further, we found that CPA invokes transcriptional activation in the L701A AR at low nanomolar concentrations similar to the T877A mutant. Analogous mutations in the glucocorticoid receptor (GR) and progesterone receptor were constructed, and we found that CPA was also converted into a potent agonist in the M560A GR. Altogether, these data offer information for structure-based drug design, elucidate flexible regions of the AR LBD, and provide insight as to how CPA antagonizes the AR and GR.
About this Structure
2OZ7 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design., Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT, J Biol Chem. 2007 May 4;282(18):13648-55. Epub 2007 Feb 20. PMID:17311914 Page seeded by OCA on Sun May 4 11:58:33 2008
